Advanced

Drug utilization research in the area of cancer drugs

Wilking, Nils; Hofmarcher, Thomas LU ; Wilking, Ulla and Jönsson, Bengt (2016) In Drug Utilization Research: Methods and Applications p.315-327
Abstract
Increased biological understanding of cancer diseases has resulted in a paradigm shift in the medical treatment of cancer. Despite encouraging advances, most cancer types are still incurable and cancer is the second most common cause of death in developed countries.

The high price of cancer drugs is a major challenge to equal access and puts heavy strains on public health care payers. After sharp increases in the 2000s, total expenditures on cancer drugs have levelled off due to patent expiration of many expensive and widely used drugs.

Cancer drug utilization studies cover a great variety of topics. Four main research areas are patient adherence, physician adherence to guidelines, effectiveness and safety (outcomes... (More)
Increased biological understanding of cancer diseases has resulted in a paradigm shift in the medical treatment of cancer. Despite encouraging advances, most cancer types are still incurable and cancer is the second most common cause of death in developed countries.

The high price of cancer drugs is a major challenge to equal access and puts heavy strains on public health care payers. After sharp increases in the 2000s, total expenditures on cancer drugs have levelled off due to patent expiration of many expensive and widely used drugs.

Cancer drug utilization studies cover a great variety of topics. Four main research areas are patient adherence, physician adherence to guidelines, effectiveness and safety (outcomes research) and access (market uptake).

Most cancer drugs are classified under Anatomical Therapeutic Chemical (ATC) group L. The use of defined daily dose (DDD) as a measurement unit is feasible for oral cancer drugs. As most cancer drugs are administered as infusions or injections at hospitals, usage is commonly measured in milligrams.

Drug utilization research in the area of cancer is faced with a lack of data. Comparisons are challenging, as prices and population bases vary across regions. The linkage of registries and health care databases that include cancer drug usage will create improved opportunities in the future. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Chapter in Book/Report/Conference proceeding
publication status
published
subject
keywords
neoplasms, antineoplastic agents, antibodies, anticarcinogenic agents
in
Drug Utilization Research: Methods and Applications
editor
Elseviers, Monique; Wettermark, Björn; Almarsdóttir, Anna Birna ; Andersen, Morten; Benko, Ria; Bennie, Marion; Eriksson, Irene; Godman, Brian; Krska, Janet; Poluzzi, Elisabetta; Taxis, Katja; Vlahović-Palčevski, Vera and Vander Stichele, Robert
pages
315 - 327
publisher
Wiley-Blackwell
ISBN
978-1-118-94978-8
language
English
LU publication?
yes
id
d2e3782b-a77f-4560-b1a7-f023b1325154
date added to LUP
2016-09-02 11:54:56
date last changed
2016-11-14 09:43:02
@inbook{d2e3782b-a77f-4560-b1a7-f023b1325154,
  abstract     = {Increased biological understanding of cancer diseases has resulted in a paradigm shift in the medical treatment of cancer. Despite encouraging advances, most cancer types are still incurable and cancer is the second most common cause of death in developed countries.<br/><br/>The high price of cancer drugs is a major challenge to equal access and puts heavy strains on public health care payers. After sharp increases in the 2000s, total expenditures on cancer drugs have levelled off due to patent expiration of many expensive and widely used drugs.<br/><br/>Cancer drug utilization studies cover a great variety of topics. Four main research areas are patient adherence, physician adherence to guidelines, effectiveness and safety (outcomes research) and access (market uptake).<br/><br/>Most cancer drugs are classified under Anatomical Therapeutic Chemical (ATC) group L. The use of defined daily dose (DDD) as a measurement unit is feasible for oral cancer drugs. As most cancer drugs are administered as infusions or injections at hospitals, usage is commonly measured in milligrams.<br/><br/>Drug utilization research in the area of cancer is faced with a lack of data. Comparisons are challenging, as prices and population bases vary across regions. The linkage of registries and health care databases that include cancer drug usage will create improved opportunities in the future.},
  author       = {Wilking, Nils and Hofmarcher, Thomas and Wilking, Ulla and Jönsson, Bengt},
  editor       = {Elseviers, Monique and Wettermark, Björn and Almarsdóttir, Anna Birna  and Andersen, Morten and Benko, Ria and Bennie, Marion and Eriksson, Irene and Godman, Brian and Krska, Janet and Poluzzi, Elisabetta and Taxis, Katja and Vlahović-Palčevski, Vera and Vander Stichele, Robert},
  isbn         = {978-1-118-94978-8},
  keyword      = {neoplasms,antineoplastic agents,antibodies,anticarcinogenic agents},
  language     = {eng},
  pages        = {315--327},
  publisher    = {Wiley-Blackwell},
  series       = {Drug Utilization Research: Methods and Applications},
  title        = {Drug utilization research in the area of cancer drugs},
  year         = {2016},
}